Andrea RiposatiHow Dante Labs Is Using Technology to Scale Genomic Testing Capabilities — London PostDante Labs, under co-founder Andrea Riposati, leverages tech to scale genomic testing capabilities.Feb 2, 2023Feb 2, 2023
Andrea RiposatiHow Dante Labs Makes Genomic Testing Available to People EverywhereWhen Italian entrepreneur Andrea Riposati identified a gap in the market for accessible genomic testing services he co-founded Dante Labs.Feb 2, 2023Feb 2, 2023
Andrea RiposatiHow Dante Labs Empowers Consumers With Personalised Genomic TestingDante Labs, under Co-Founder Andrea Riposati, empowers consumers through personalised genomic testing.Feb 2, 2023Feb 2, 2023
Andrea RiposatiDante Labs’ CEO Andrea Riposati Is Inspired to Bring Whole Genome Sequencing to Patients WorldwideDante Labs’ CEO Andrea Riposati brings whole genome sequencing worldwide, increasing accessibility to the important procedure.Jan 13, 2023Jan 13, 2023
Andrea RiposatiHow Andrea Riposati Grew Dante Labs’ Annual Revenue to $100 Million By Making Genomics Testing…As the CEO of Dante Labs, Andrea Riposati has broadened global access to direct-to-consumer genome sequencing, reshaping the landscape.Dec 21, 2022Dec 21, 2022
Andrea RiposatiDante Labs: Innovating Whole Genome SequencingDante Labs, under CEO and Co-Founder Andrea Riposati, innovates whole genome sequencing.Dec 5, 2022Dec 5, 2022
Andrea RiposatiCEO Spotlight: Andrea Riposati of Dante Labs — CEOWORLD magazineAndrea Riposati is globally recognized as an entrepreneur and the CEO and co-founder of Dante Labs, which he founded with Mattia Capulli…Dec 5, 2022Dec 5, 2022
Andrea RiposatiWhole-Genome Sequencing as an Asset for LifeAndrea Riposati, CEO and Co-Founder of Dante Labs, sat down for an in-depth interview about whole genome sequencing.Nov 17, 2022Nov 17, 2022
Andrea RiposatiDante Genomics Unveils Digital Health Population Genomic Programs at the United Nations General…Dante Genomics, led by Co-Founder and CEO Andrea Riposati, recently unveiled a digital health population genomic program.Oct 4, 2022Oct 4, 2022
